Impact of Desensitization on Antiviral Immunity in HLA-Sensitized Kidney Transplant Recipients
Table 2
CMV, EBV, and BKV viremia in DES and non-DES patients.
Viral DNA detected
Kidney transplant patients
value
DES group ()
Non-DES group ()
CMV-PCR > 5.0 copies/PCR
Viremia rate (% ± SE)
30.3 ± 3.6
35.7 ± 2.9
0.19
1st viremia (m post-Tx)
5.8 ± 10.3
7.7 ± 14.1
0.23
Peak levels (copies/PCR)
420 ± 1077
2730 ± 18374
0.12
Duration (m)
0.7 ± 0.7
1.1 ± 2.0
0.02
CMV-PCR > 30 copies/PCR
Vremia rate (% ± SE)
16.1 ± 2.1
25.2 ± 2.7
0.04
1st viremia (m post-Tx)
3.7 ± 4.0
6.7 ± 12.5
0.02
Peak levels (copies/PCR)
699 ± 1331
3904 ± 21887
0.13
Duration (m)
0.8 ± 0.5
1.4 ± 2.4
0.01
CMV-PCR > 50 copies/PCR
Viremia rate (% ± SE)
13.5 ± 1.9
22.5 ± 2.7
<0.05
1st viremia (m post-Tx)
3.4 ± 3.1
7.1 ± 13.3
0.01
Peak levels (copies/PCR)
811 ± 1410
4462 ± 23360
0.13
Duration (m)
0.8 ± 0.6
1.5 ± 2.5
0.01
EBV-PCR > 5.0 copies/PCR
Viremia rate (% ± SE)
13.6 ± 3.8
30.0 ± 4.5
<0.001
1st viremia (m post-Tx)
18.8 ± 19.5
13.1 ± 19.3
0.20
Peak levels (copies/PCR)
171 ± 512
74 ± 141
0.36
Duration (m)
6.7 ± 17.5
4.5 ± 6.4
0.54
EBV-PCR > 30 copies/PCR
Viremia rate (% ± SE)
2.9 ± 1.1
11.3 ± 2.8
0.001
1st viremia (m post-Tx)
14.5 ± 20.2
9.4 ± 15.5
0.52
Peak levels (copies/PCR)
474 ± 785
157 ± 187
0.29
Duration (m)
17.1 ± 26.6
7.5 ± 7.7
0.34
EBV-PCR > 50 copies/PCR
Viremia rate (% ± SE)
2.3 ± 1.0
6.4 ± 1.5
0.01
1st viremia (m post-Tx)
9.4 ± 7.8
6.4 ± 8.4
0.47
Peak levels (copies/PCR)
691 ± 884
216 ± 205
0.29
Duration (m)
23.6 ± 30.6
8.3 ± 8.1
0.32
PTLD, (%)
0
0
na
BKV-PCR > 250 copies/ml
Viremia rate (% ± SE)
20.1 ± 2.5
17.1 ± 1.9
0.21
1st viremia (m post-Tx)
5.2 ± 5.4
6.6 ± 8.7
0.25
Peak levels (copies/PCR)
1
0.31
Duration (m)
5.0 ± 10.4
5.8 ± 11.1
0.70
BKV-PCR >1500 copies/ml
Viremia rate (% ± SE)
11.2 ± 1.8
13.0 ± 1.8
0.72
1st viremia (m post-Tx)
4.2 ± 4.0
6.4 ± 9.7
0.14
Peak levels (copies/PCR)
0.28
Duration (m)
7.8 ± 12.8
7.3 ± 12.2
0.84
BKV-PCR >2500 copies/ml
Viremia rate (% ± SE)
10.9 ± 1.8
10.7 ± 1.7
0.60
1st viremia (m post-Tx)
4.3 ± 4.1
6.9 ± 10.6
0.12
Peak levels (copies/PCR)
0.30
Duration (m)
8.0 ± 13.0
8.4 ± 13.2
0.88
BKAN, (%)
4 (1.1)
10 (1.9)
0.35
Time for BKAN (m post-Tx)
12.3 ± 10.1
11.6 ± 7.1
0.92
The viremia rates (% ± standard error [SE]) at 5 years after transplant (Tx) were estimated by the Kaplan-Meier method and the group differences were assessed by the log-rank test. Results for 1st viremia, peak levels, duration, and time for BKAN are mean ± standard deviation. m post-Tx: months after transplant, PTLD: posttransplant lymphoproliferative disorder, and BKAN: BKV-associated nephropathy.
